Boston Scientific Corporation (BSX) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDT
Company Participants
Lauren Tengler – Director of Investor Relations
Michael Mahoney – Chairman, President & CEO
Jonathan Monson – Executive VP & CFO
Ken Stein – Senior VP & Global Chief Medical Officer
Conference Call Participants
Robert Marcus – JPMorgan Chase & Co, Research Division
Larry Biegelsen – Wells Fargo Securities, LLC, Research Division
Joanne Wuensch – Citigroup Inc., Research Division
Frederick Wise – Stifel, Nicolaus & Company, Incorporated, Research Division
Michael Polark – Wolfe Research, LLC
Travis Steed – BofA Securities, Research Division
Matthew Taylor – Jefferies LLC, Research Division
Marie Thibault – BTIG, LLC, Research Division
Jayson Bedford – Raymond James & Associates, Inc., Research Division
Joshua Jennings – TD Cowen, Research Division
Presentation
Operator
Good morning, and welcome to the Boston Scientific Second Quarter 2026 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.
Lauren Tengler
Director of Investor Relations
Thank you, Drew, and thanks to everyone for joining us. With me on today’s call are Mike Mahoney, Chairman and Chief Executive Officer; and Jon Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Jon will be joined by our Chief Medical Officer, Dr. Ken Stein. We issued a press release earlier this morning announcing our Q2 2026 results, which included reconciliations of the non-GAAP measures used in this release. The release as well as the reconciliations of non-GAAP measures used in today’s call can be found on the Investor Relations section of our website.
Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue further excludes certain acquisitions and divestitures for which there is less than a full period of
